BIORIENT Acupuncture Clinic
|
Thesis:
Csoka, K.: The Fluorometric Microculture Cytotoxicity Assay (FMCA) in assessment
of the clinical activity of cytotoxic drugs. With special reference to ovarian
carcinoma. Comprehensive Summary, Uppsala University, Faculty of Medicine, 690.
Original Papers:
1. Gati, I., Bergstrom, M., Westerberg, G., Csoka, K., et al. (1990). Effects of prostaglandin
and leukotrine inhibitors on the growth of human glioma spheroids. Eur J Cancer, 26, (7) 802-807.
2. Gati, I., Bergstrom, M., Csoka, K., et al. (1990). Effects of the 5-lypoxygenase inhibitors
AA-863 and U-60, 275 on human glioma cell lines
Prostaglandins Leukotrines & Essential Fatty Acids, 40, (2) 117-124.
3. Larsson, R., Fridborg, H., Csoka, K., et al. (1992). Cytotoxic actions of cyclosporins on
human tumor cell lines is not dependent on immunosuppressive activity. Anticancer Res., 12, 1581-
1586.
4. Larsson, R., Jonsson, B., Csoka, K., et al. (1992). Selective cytotoxicity activity of
cyclosporins against tumor cells from patients with chronic lymphocytic leukemia.
Eur J Pharmacology, 228, 237-240.
5. Nygren, P., Fridborg, H., Csoka, K., et al. (1994). Detection of tumor-specific drug activity
in vitro using the fluorometric microculture cytotoxicity assay and primary cultures of tumor
cells from patients. Int J Cancer, 56, 715-720.
6. Larsson. R., Fridborg, H., Liliemark, J., Csoka, K., et al. (1994). In vitro activity of 2-
delorodeoxyadenosine (CdA) in primary cultures of human hematological and solid tumors.
Eur J Cancer, 30A, 1022-1026.
7. Fridborg, H., Nygren, P., Csoka., K., et al. (1994). Activity of Cyclosporin-A and SDZ 833 as
cytotoxic drug resistance modifiers in primary cultures of hematological and solid tumors.
Br J Cancer, 70, 11-17.
8. Csoka, K., et al. (1994). Cytotoxic drug sensitivity testing of tumor cells from pa
tients with ovarian carcinoma using the Fluorometric Microculture Cytotoxicity Assay (FMCA).
Gynecol Oncol., 54, 163-170.
9. Nygren, P., Csoka, K., et al. (1995). The cytotoxic activity of Taxol in primary cultures of
tumour cells from patients is partly mediated by Chremophor EL. Br J Cancer, 71, 478-481.
10. Csoka, K., et al., (1995). Evaluation of the cytotoxic activity of Gemcitabine in primary
cultures of tumor cells from patients with hematologic and solid tumors. Semin Oncol., 22, 47-53.
11. Csoka, K., et al. (1995) Selective sensitivity of solid tumors to suramin in primary cultures
of tumor cells from patients. Int J Cancer, 63, 356-360.
12. Dhar, S., Nygren, P., Csoka, K., et al. (1996). Anticancer drug characterization using a
human cell line panel representing defined types of drug resistance. Br J Cancer, 74, 888-896.
13. Jonsson, B., Liminga, G., Csoka, K., et al. (1996. Cytotoxic activity of Calcein
acetoxymethyl ester (Calcein/AM) against primary cultures of human hematological and solid
tumors. Eur J Cancer, 32A, 883-887.
14. Csoka, K., et al. (1997). Differential activity of Chremophor EL and Paclitaxel in patient’s
tumor cells and human carcinoma cell lines in vitro. Cancer, 79/6, 1225-1233.
15. Fridborg, H., Nygren, P., Csoka, K., et al. (1996). Cytotoxic activity of Vinorelbine in cell
lines and fresh human tumor cells. J Exper Therapeutics & Oncology, 1, 286-295.
16. Jonsson, E., Fridborg, H., Csoka, K., et al. (1997). Cytotoxic activity of Topotecan in
human tumor cell lines and primary cultures of human tumour cells from patients. Br J Cancer, 76,
211-219.
17. Csoka, K., et al. (1997). In vitro determination of cytotoxic drug-response in ovarian
carcinoma using the fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer, 72, 108-
1012.
18. Nygren, P., Csoka, k., et al. (1999). Activity of standard and investigational cytotoxic
drugs in primary cultures of tumor cells from patients with kidney and urinary bladder carcinomas.
J Urol., 162/6, 2200-2204.
19. von Heideman, A., Sandstrom, M., Csoka, K., et al. (2000). Evaluation of drug interactions
in the established FEC regimen in primary cultures of tumor cells from patients. Ann Oncol., 10,
1301-1307.
20. Dhar, S., Gullbo, J., Csoka, K., et al. (2000). Antitumour activity of suramin analogues in
human tumour cell lines and primary cultures of tumour cells from patients. Eur J Cancer, 6, 803-
809.
Original papers, manuscripts:
1. Larsson, R., Csoka, K., et al. (1998). The ratio of systematic exposure at maximum
tolerated dose and in vitro potency as a tool for prediction of clinical utility of anticancer agents
in ovarian carcinoma. Manuscript.
Abstracts:
1. Csoka, K., et al. (1992). A feasibility study of the Fluorometric Microculture Cytotoxicity
Assay (FMCA) for in vitro prediction of chemotherapeutic drug resistance in solid tumors.
Anticancer Res A:472.
2. Csoka, K., et al. (1993). The Fluorometric Microculture Cytotoxicity Assay (FMCA) a
feasible in vitro test of ovarian cancer chemosensitivity. Fourth Biennial Meeting of the
International Gynecologic Cancer Society, Aug. 29-Sept. 2, Stockholm, Sweden, A:267.
3. Uddenfelt, U., Fridborg, H., Csoka, K., et al. (1993). Determination of in vitro
chemosensitivity of malignant tumors in children (Bastemning in vitro av cytostatikakanslighet I
maligna tumorer hos barn). NOPHOs XI arsmote.
4. Csoka, K., et al. (1994). P-glycoprotein (P-gp), p53 and bcl-2 expression in patient samples
of ovarian carcinoma: Correlation with in vitro chemosensitivity and resistance modification. 1st
International Conference on Reversal of Multidrug Resistance in Cancer, 1-3 Sept. St Gallen,
Switzerland, A:137.
5. Csoka, K., et al. (1995). Chemosensitivity of ovarian carcinoma. Resistance patterns and
initial in vitro/in vivo correlations using the Fluorometric Microculture Cytotoxicity Assay. Fifth
Biennial Meeting of the International Gynecologic Cancer Society, Sept. 4-8, Philadelphia, PA,
USA, A:175.
6. Dhar, S., Nygren, P., Csoka, K., et al. (1997). Feasibility of a non-clonogenic assay of
primary tumor cells for new anticancer drug screening. 88th Annual Meeting of the American
Association for Cancer Research, Apr. 12-16, San Diego, CA, USA, A:4070.
7. Fridborg, H., Jonsson, E., Csoka, K., et al. (1997). Capability of a non-clonogenic
cytotoxicity assay (FMCA) to detect disease-specific activity of cytotoxic drugs in fresh human
tumor cells. 88th Annual Meeting of the American Association for Cancer Research, Apr. 12-
16, San Diego, CA, USA, A: 4069.
